SOFT TISSUE SARCOMA

This early-stage study tests a treatment made from a patient's own immune cells, modified to recognize and attack solid tumors. It includes children and young adults (ages 1–30) whose cancer has returned or not responded to standard therapy. The goal is to find a safe dose and se…

This study tests an oral drug called LOXO 292 in children and teens with advanced solid or brain tumors that have a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors or stop them from growing. About 36 participants will receive the drug, a…

This early-phase study tests a drug called ADI-PEG 20 combined with chemotherapy (ifosfamide) and radiation before surgery for soft tissue sarcoma. The goal is to find the safest dose and see if it helps shrink tumors. Only 6 patients with intermediate or high-grade sarcomas of t…

This study tests a new approach for people with advanced soft tissue sarcoma that cannot be easily removed with surgery alone. Participants receive injections of a modified virus (TVEC) directly into the tumor along with standard radiation therapy before surgery. The goal is to s…

This early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…

This study tests a shorter course of high-dose radiation (hypofractionated radiotherapy) for people with soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this approach can control the tumor for at least two years while causing fewer side effects to nea…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…

This study compares two common blood thinners, aspirin and low molecular weight heparin (LMWH), to prevent dangerous blood clots after orthopedic surgery for cancer. About 2,868 adults having surgery on the pelvis or leg for bone metastases or sarcoma will be enrolled. The goal i…

This study tests whether giving a lower dose of radiation to a smaller area after surgery for soft tissue sarcoma can control the cancer just as well as standard treatment. The goal is to reduce long-term side effects while keeping the cancer from coming back. About 65 adults who…

This study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink or slow advanced dedifferentiated liposarcoma, a rare soft tissue cancer. About 16 adults whose cancer has returned, spread, or cannot be removed by surgery will receive the treatment. The mai…

This phase 2 trial tests a personalized cell therapy called LN-145 for people with certain advanced cancers (like ovarian, breast, thyroid, or bone cancers) that have not responded to treatment or have returned. The therapy uses a patient's own immune cells, taken from their tumo…

This study tests a combination of a cancer-killing virus (T-VEC) and radiation therapy in 40 adults with newly diagnosed soft tissue sarcoma that can be surgically removed. The goal is to see if this approach destroys more tumor cells before surgery and to check for side effects.…

This study tests whether combining two drugs (atezolizumab and tivozanib) can help the immune system attack cancers that usually don't respond to immunotherapy, like certain prostate, pancreatic, and breast cancers. About 29 adults with advanced or metastatic disease who have alr…

This study tests a technique called image-guided radiation therapy (IGRT) for children and young adults with bone or soft tissue tumors. IGRT uses detailed scans (CT, MRI, PET) to target the tumor very precisely, aiming to destroy the cancer while protecting healthy tissue. The g…

This early-phase study tests whether injecting a modified herpes virus (T-VEC) directly into tumors, combined with radiation therapy before surgery, is safe and can shrink advanced soft tissue sarcomas. About 8 to 46 adults with sarcoma that cannot be easily removed will receive …

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This early-stage study tests whether a personalized immune cell therapy called TIL is safe and can fight cancer in children, teenagers, and young adults (ages up to 21) with solid tumors that have come back or stopped responding to standard treatments. Participants receive their …

This study looks at whether a personalized risk assessment tool called PERSARC can help patients with soft-tissue sarcoma make better-informed treatment decisions. About 120 adults with high-grade sarcoma in their arms or legs will either receive standard care or use PERSARC to u…

This study tests whether giving radiation over just 5 days before surgery for soft tissue sarcoma is practical and acceptable. About 16 adults with sarcoma in an arm, leg, or trunk will receive this shorter radiation course. The goal is to see if patients choose this option and h…